Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

LGND

Ligand Pharmaceuticals, Inc.

May 28 • 11:54AM ET

85.45

Dollar change -0.95
Percentage change -1.10	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: IJR VTI IWM VB VBR VXF IJS PJP IWN IBB

Index	RUT	P/E	16.06	EPS (ttm)	5.32	Insider Own	2.46%	Shs Outstand	17.56M	Perf Week	-1.36%
Market Cap	1.53B	Forward P/E	15.41	EPS next Y	5.54	Insider Trans	-9.03%	Shs Float	17.52M	Perf Month	21.09%
Income	96.34M	PEG	0.80	EPS next Q	0.99	Inst Own	93.50%	Short Float	4.90%	Perf Quarter	-4.20%
Sales	118.31M	P/S	12.97	EPS this Y	-23.81%	Inst Trans	-0.32%	Short Ratio	4.56	Perf Half Y	42.20%
Book/sh	45.00	P/B	1.90	EPS next Y	19.47%	ROA	11.17%	Short Interest	0.86M	Perf Year	19.21%
Cash/sh	17.29	P/C	4.94	EPS next 5Y	20.00%	ROE	13.26%	52W Range	49.24 - 94.57	Perf YTD	19.64%
Dividend Est.	-	P/FCF	47.72	EPS past 5Y	-13.18%	ROI	11.87%	52W High	-9.64%	Beta	1.05
Dividend TTM	-	Quick Ratio	19.51	Sales past 5Y	-3.89%	Gross Margin	64.12%	52W Low	73.54%	ATR (14)	2.70
Dividend Ex-Date	Jul 02, 2010	Current Ratio	20.70	EPS Y/Y TTM	290.26%	Oper. Margin	-1.18%	RSI (14)	60.79	Volatility	2.61% 3.47%
Employees	58	Debt/Eq	0.01	Sales Y/Y TTM	-45.70%	Profit Margin	81.43%	Recom	1.20	Target Price	116.80
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	103.66%	Payout	0.00%	Rel Volume	0.37	Prev Close	86.40
Sales Surprise	10.94%	EPS Surprise	43.88%	Sales Q/Q	-29.56%	Earnings	May 07 AMC	Avg Volume	188.15K	Price	85.45
SMA20	5.74%	SMA50	11.06%	SMA200	25.18%	Trades		Volume	28,269	Change	-1.10%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-14-21	Resumed	Stephens	Overweight	$200
Feb-04-21	Reiterated	H.C. Wainwright	Buy	$229 → $310
Oct-06-20	Initiated	Barclays	Overweight	$156
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy	$135
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight	$110 → $132
Jun-11-19	Initiated	Barclays	Equal Weight	$131
May-03-19	Reiterated	H.C. Wainwright	Buy	$254 → $214
Mar-06-19	Reiterated	H.C. Wainwright	Buy	$281 → $254
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$270 → $280
Sep-11-18	Reiterated	Argus	Buy	$260 → $300
Aug-17-18	Initiated	Goldman	Neutral	$256
Aug-08-18	Downgrade	ROTH Capital	Buy → Neutral
Jun-21-18	Initiated	Argus	Buy	$260
Dec-27-17	Reiterated	H.C. Wainwright	Buy	$163 → $169
Sep-05-17	Resumed	H.C. Wainwright	Buy	$150
Oct-05-16	Reiterated	H.C. Wainwright	Buy	$146 → $160
Aug-05-16	Downgrade	Deutsche Bank	Hold → Sell	$104 → $110

Show Previous Ratings

May-23-24 04:59PM	Ligand to Participate in Upcoming Investor Conferences (Business Wire)
May-20-24 06:00AM	3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off (InvestorPlace)
May-13-24 12:00PM	Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
May-10-24 08:50AM	Ligand (LGND) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-09-24 09:40AM	Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year? (Zacks) +7.17%
01:22PM	Loading…
May-08-24 01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey) +9.75%
12:19PM	Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates (Zacks)
May-07-24 09:01PM	LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:40PM	Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates (Zacks)
04:00PM	Ligand Reports First Quarter 2024 Financial Results (Business Wire)
11:29AM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:30AM	Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement (Business Wire)
Apr-23-24 08:31AM	Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
Apr-17-24 09:55AM	Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know (Zacks)
Apr-08-24 08:15AM	Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference (Business Wire)
06:00PM	Loading…
Apr-05-24 06:00PM	Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts (Zacks)
Apr-04-24 09:30AM	Wall Street Analysts Think Ligand (LGND) Is a Good Investment: Is It? (Zacks)
09:00AM	Investors Heavily Search Ligand Pharmaceuticals Incorporated (LGND): Here is What You Need to Know (Zacks)
Apr-03-24 09:00AM	Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI (Business Wire)
Apr-01-24 06:15PM	Ligand Pharmaceuticals (LGND) Ascends While Market Falls: Some Facts to Note (Zacks)
Mar-28-24 11:30AM	Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-26-24 06:15PM	Ligand Pharmaceuticals (LGND) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Mar-21-24 09:00AM	Here is What to Know Beyond Why Ligand Pharmaceuticals Incorporated (LGND) is a Trending Stock (Zacks)
Mar-20-24 06:00PM	Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider (Zacks)
Mar-19-24 09:30AM	Ligand (LGND) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Mar-14-24 06:00PM	Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors (Zacks)
Mar-07-24 09:00AM	Is Trending Stock Ligand Pharmaceuticals Incorporated (LGND) a Buy Now? (Zacks)
Mar-05-24 04:01PM	Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference (Business Wire)
Mar-04-24 08:00AM	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-29-24 09:30AM	Wall Street Analysts See Ligand (LGND) as a Buy: Should You Invest? (Zacks) -5.93%
07:34AM	Loading…
Feb-28-24 07:34AM	Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges (Zacks) -5.44%
Feb-27-24 07:00AM	Ligand Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire) +19.86%
Feb-22-24 04:01PM	Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa (Business Wire)
Feb-16-24 08:00AM	Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires (Business Wire)
Feb-13-24 04:01PM	Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (Business Wire) -6.13%
Feb-01-24 05:00PM	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-10-24 07:30PM	Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene (GlobeNewswire)
Jan-05-24 04:30PM	U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum (Business Wire)
Dec-12-23 12:01PM	Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance (Business Wire)
09:00AM	Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life (GlobeNewswire)
09:00AM	Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations (GlobeNewswire)
Dec-11-23 09:00AM	Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology (GlobeNewswire)
Dec-06-23 04:02PM	Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City (Business Wire)
Dec-01-23 08:20AM	Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications (GlobeNewswire)
Nov-28-23 09:01AM	Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-09-23 04:47PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:01PM	Ligand Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-06-23 09:00AM	Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial (GlobeNewswire)
Nov-01-23 08:00AM	Ligand Acquires Royalty on Sanofis TZIELD for $20 Million (Business Wire)
Oct-25-23 04:01PM	Ligand To Report Third Quarter 2023 Financial Results On November 8 (Business Wire)
Oct-18-23 08:00AM	Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026 (GlobeNewswire)
Oct-09-23 06:15PM	Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider (Zacks)
Oct-03-23 06:00PM	Ligand Pharmaceuticals (LGND) Stock Moves -0.71%: What You Should Know (Zacks)
Oct-02-23 09:00AM	Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast Cancer (GlobeNewswire)
09:00AM	Sermonix Pharmaceuticals Announces Results of ELAINE-1 Exploratory Analysis Evaluating Effect of Patient Characteristics on Baseline Genitourinary Symptoms (GlobeNewswire)
Sep-27-23 09:00AM	Ligand Acquires Assets of Novan, Inc. for $12.2 Million (Business Wire)
Sep-26-23 05:05PM	Ligand Appoints Martine Zimmermann to its Board of Directors (Business Wire)
Sep-22-23 09:00AM	Ligands Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (Business Wire)
Sep-21-23 09:20AM	Ligands Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control (Business Wire)
Sep-18-23 05:17PM	Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio (Business Wire)
Sep-01-23 10:02PM	Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Aug-08-23 04:01PM	Ligand Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-27-23 01:30PM	Ligands Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials (Business Wire)
Jul-25-23 04:30PM	Ligand To Report Second Quarter 2023 Financial Results On August 8 (Business Wire)
Jul-17-23 08:59AM	Ligand Offers $15 Million to Acquire Assets of Novan, Inc. (Business Wire)
08:45AM	Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection (GlobeNewswire)
Jun-29-23 09:00AM	Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting (GlobeNewswire)
Jun-21-23 08:00PM	LGND: Lowering target price to $81.00 (Argus Research)
Jun-09-23 09:40AM	Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-06-23 11:40AM	LGND or ILMN: Which Is the Better Value Stock Right Now? (Zacks)
11:10AM	UnitedHealth (UNH) Intends to Buy Amedisys to Boost Home-Health (Zacks)
Jun-05-23 11:49AM	Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat (Zacks) -5.72%
09:01AM	Sermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast Cancer (GlobeNewswire)
Jun-02-23 12:39PM	FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer (Zacks) +5.77%
12:35PM	Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study (Zacks)
Jun-01-23 11:29AM	Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates (Zacks)
May-30-23 07:01PM	3 Stocks That Smart Investors Should Be Flocking to Now (InvestorPlace)
May-25-23 05:00PM	Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023 (GlobeNewswire)
May-24-23 09:55AM	Wall Street Analysts Think Ligand (LGND) Could Surge 44.42%: Read This Before Placing a Bet (Zacks)
09:40AM	Has Anebulo Pharmaceuticals (ANEB) Outpaced Other Medical Stocks This Year? (Zacks)
May-17-23 01:59PM	Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study (Zacks)
08:07AM	Zacks.com featured highlights include J.B. Hunt Transport Services, Archer-Daniels-Midland, NVIDIA, Tractor Supply and AmerisourceBergen (Zacks)
May-16-23 09:56AM	Here's Why Biogen (BIIB) Stock is Up 12.6% This Year So Far (Zacks)
07:30AM	Ligands Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) (Business Wire)
07:00AM	Load Up on These 5 Exceptional Relative Price Strength Stocks (Zacks)
May-12-23 12:08PM	ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why (Zacks)
11:34AM	FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing (Zacks)
May-11-23 12:25PM	Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View (Zacks)
May-08-23 12:32PM	Ligand (LGND) Up 3% on Raised '23 View, Beats on Q1 Earnings (Zacks)
09:55AM	Wall Street Analysts Believe Ligand (LGND) Could Rally 38.66%: Here's is How to Trade (Zacks)
May-06-23 10:13AM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ? (Simply Wall St.)
May-05-23 10:00AM	Best Momentum Stocks to Buy for May 5th (Zacks)
May-04-23 05:45PM	Ligand Pharmaceuticals (LGND) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
04:01PM	Ligand Reports First Quarter 2023 Financial Results (Business Wire)
06:26AM	10 Best Small-Cap Growth Stocks to Buy Now (Insider Monkey)
May-02-23 08:30PM	2 Medical Stocks to Buy Before Earnings (Zacks)
12:06PM	Vertex (VRTX) Q1 Earnings Top Estimates, Revenues Up Y/Y (Zacks)
11:40AM	LGND vs. REGN: Which Stock Is the Better Value Option? (Zacks)
Apr-28-23 02:04PM	Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Up Y/Y (Zacks)
Apr-27-23 09:04AM	Alkermes (ALKS) Q1 Earnings & Revenues Beat Estimates (Zacks)

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Espinoza Octavio	Chief Financial Officer	May 17 '24	Option Exercise	55.71	6,917	385,346	28,535	May 17 07:59 PM
Espinoza Octavio	Chief Financial Officer	May 17 '24	Sale	86.66	5,156	446,844	23,379	May 17 07:59 PM
Espinoza Octavio	Chief Financial Officer	May 16 '24	Sale	86.00	2,264	194,712	21,618	May 17 07:59 PM
Espinoza Octavio	Chief Financial Officer	May 15 '24	Sale	86.01	5,873	505,148	23,882	May 17 07:59 PM
Korenberg Matthew E	President & Chief Operating	May 14 '24	Sale	85.10	14,158	1,204,912	86,263	May 15 07:34 PM
Korenberg Matthew E	President & Chief Operating	May 13 '24	Sale	84.54	3,440	290,828	100,421	May 15 07:34 PM
Reardon Andrew	Chief Legal Officer &	May 09 '24	Option Exercise	52.27	10,000	522,700	32,205	May 13 05:32 PM
Reardon Andrew	Chief Legal Officer &	May 09 '24	Sale	83.04	10,000	830,449	22,205	May 13 05:32 PM
Gray Nancy Ryan	Director	May 09 '24	Sale	83.20	934	77,713	5,633	May 17 08:00 PM
Aryeh Jason	Director	Apr 30 '24	Option Exercise	52.30	2,406	125,834	76,828	May 02 06:07 PM
KOZARICH JOHN W	Director	Apr 24 '24	Option Exercise	39.35	2,893	113,840	42,523	Apr 26 06:35 PM
Davis Todd C	Chief Executive Officer	Mar 25 '24	Option Exercise	57.39	16,015	919,147	120,160	Mar 27 05:47 PM
Aryeh Jason	Director	Mar 05 '24	Option Exercise	39.35	2,893	113,840	74,422	Mar 06 05:28 PM
Sabba Stephen L	Director	Mar 05 '24	Option Exercise	0.00	2,893	0	30,819	Mar 07 01:27 PM
Sabba Stephen L	Director	Mar 05 '24	Sale	74.30	1,893	140,650	28,926	Mar 07 01:27 PM
Espinoza Octavio	Chief Financial Officer	Feb 28 '24	Option Exercise	56.62	1,264	71,564	29,895	Feb 29 06:50 PM
Espinoza Octavio	Chief Financial Officer	Feb 28 '24	Sale	88.46	140	12,384	29,755	Feb 29 06:50 PM
Davis Todd C	CHIEF EXECUTIVE OFFICER	Sep 22 '23	Buy	59.38	4,000	237,529	73,090	Sep 25 04:44 PM

Open in Screener

OBIO

Orchestra BioMed Holdings Inc

May 28 • 11:54AM ET

5.90

Dollar change +0.60
Percentage change 11.32	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWM IWO SCHA VTWO IWC SCHB VTWG RYLD

Index	RUT	P/E	-	EPS (ttm)	-1.46	Insider Own	42.43%	Shs Outstand	35.78M	Perf Week	12.81%
Market Cap	211.16M	Forward P/E	-	EPS next Y	-1.69	Insider Trans	0.00%	Shs Float	20.61M	Perf Month	34.40%
Income	-51.64M	PEG	-	EPS next Q	-0.40	Inst Own	36.48%	Short Float	4.04%	Perf Quarter	-6.94%
Sales	2.22M	P/S	95.12	EPS this Y	-7.06%	Inst Trans	-31.90%	Short Ratio	20.97	Perf Half Y	-10.13%
Book/sh	1.60	P/B	3.69	EPS next Y	-6.82%	ROA	-47.18%	Short Interest	0.83M	Perf Year	-61.89%
Cash/sh	2.10	P/C	2.81	EPS next 5Y	-	ROE	-65.81%	52W Range	4.22 - 17.35	Perf YTD	-35.38%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-88.51%	52W High	-65.99%	Beta	0.29
Dividend TTM	-	Quick Ratio	7.33	Sales past 5Y	-7.29%	Gross Margin	75.07%	52W Low	39.81%	ATR (14)	0.44
Dividend Ex-Date	-	Current Ratio	7.34	EPS Y/Y TTM	-160.83%	Oper. Margin	-2454.15%	RSI (14)	64.26	Volatility	8.55% 8.79%
Employees	56	Debt/Eq	0.03	Sales Y/Y TTM	90.38%	Profit Margin	-2330.46%	Recom	1.00	Target Price	16.33
Option/Short	No / Yes	LT Debt/Eq	0.02	EPS Q/Q	4.93%	Payout	-	Rel Volume	3.97	Prev Close	5.30
Sales Surprise	-34.74%	EPS Surprise	4.28%	Sales Q/Q	-46.74%	Earnings	May 13 AMC	Avg Volume	39.75K	Price	5.90
SMA20	18.92%	SMA50	19.43%	SMA200	-8.19%	Trades		Volume	63,263	Change	11.32%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-19-24	Initiated	Jefferies	Buy	$14
Feb-24-23	Initiated	Piper Sandler	Overweight	$15
Feb-07-23	Initiated	Chardan Capital Markets	Buy	$20

May-22-24 08:43AM	Orchestra BioMed to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-24 09:53PM	OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:05PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:58PM	Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-30-24 08:30AM	Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents (GlobeNewswire)
08:00AM	Loading…
08:00AM	Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024 (GlobeNewswire)
Mar-27-24 04:17PM	Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update (GlobeNewswire)
Mar-26-24 08:00AM	Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors (GlobeNewswire) +5.20%
Mar-13-24 08:00AM	Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting (GlobeNewswire)
Mar-07-24 08:00AM	Orchestra BioMed to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.62%
Mar-06-24 08:37AM	Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients (GlobeNewswire)
Feb-26-24 08:00AM	Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years (GlobeNewswire)
Feb-16-24 09:13AM	Why Orchestra BioMed (OBIO) Might Surprise This Earnings Season (Zacks) -8.45%
Jan-08-24 07:30AM	Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients (GlobeNewswire) +9.38%
Nov-13-23 04:21PM	Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +14.61%
04:42PM	Loading…
Nov-09-23 04:42PM	Orchestra BioMed to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-30-23 03:52PM	Billionaire Marc Lasrys Top 10 Stock Picks (Insider Monkey)
Sep-22-23 11:27AM	Lab Notes: Main Line firm spins off company that will focus on OTC product pipeline (American City Business Journals)
Sep-19-23 02:37PM	Rebel's Edge - September 19: $NIO, $BHC, $OBIO, and the Firing of MSU's Football Coach (TheStreet.com) +27.61%
07:30AM	Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT for the Treatment of Hypertension in Pacemaker Patients (GlobeNewswire)
Sep-06-23 05:00PM	Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors (GlobeNewswire)
Aug-10-23 04:34PM	Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +7.05%
Aug-08-23 08:30AM	Orchestra BioMed Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon in Patients with Coronary In-Stent Restenosis (GlobeNewswire)
Jul-27-23 09:47AM	Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) stock most popular amongst retail investors who own 36%, while hedge funds hold 28% (Simply Wall St.) -14.00%
Jun-28-23 02:16PM	Why Shares of Orchestra BioMed Holdings Jumped Wednesday (Motley Fool) +24.85%
Jun-26-23 08:00AM	Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes (GlobeNewswire) -9.81%
Jun-07-23 08:30AM	Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer (GlobeNewswire) -6.42%
Jun-01-23 08:00AM	Orchestra BioMed to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +8.93%
May-12-23 09:15AM	Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-11-23 05:39AM	3 Stocks That Already Doubled in 2023 and Could Keep Climbing (Motley Fool) +10.12%
06:05AM	Loading…
Mar-27-23 06:05AM	Orchestra BioMed Holdings Full Year 2022 Earnings: US$14.60 loss per share (vs US$10.90 loss in FY 2021) (Simply Wall St.)
Mar-24-23 03:52PM	Why Shares of Orchestra BioMed Jumped This Week (Motley Fool)
Mar-07-23 08:00AM	Orchestra BioMed to Present at Upcoming Investor Conferences (GlobeNewswire) -6.77%
Feb-24-23 08:00AM	Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT and Virtue® SAB at CRT 2023 (GlobeNewswire)
Feb-07-23 08:00AM	Orchestra BioMed Strengthens Senior Leadership Team (GlobeNewswire)

Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company was founded on May 25, 2020 and is headquartered in New Hope, PA.

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

LGND

Ligand Pharmaceuticals, Inc.

OBIO

Orchestra BioMed Holdings Inc

Upgrade your FINVIZ experience